JMR-132

General Information


DRACP ID  DRACP01850

Peptide Name   JMR-132

Sequence  YADAIFTAXXHKVLGQLSAHKLLQDIMSR

Sequence Length  29

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Hormone stimulating peptides GHRH antagonists



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
LNCaP Prostate carcinoma Carcinoma ~88%Inhibition=5 µM MTT assay 70-72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X(9)=homoArg; X(10)=Tyr methyl ether

Chiral  L



Physicochemical Information


Formula  C136H216N38O36S

Absent amino acids  CENPW

Common amino acids  AL

Mass  371115

Pl  9.26

Basic residues  5

Acidic residues  2

Hydrophobic residues  12

Net charge  3

Boman Index  -2630

Hydrophobicity  12.41

Aliphatic Index  104.48

Half Life 
  /

Extinction Coefficient cystines  1490

Absorbance 280nm  53.21

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 28130121

Title  Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth

Doi 10.1016/j.peptides.2017.01.009

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.